Immortal Dragons Champions a New Frontier in Longevity with Strategic Investment in Etheros Pharmaceuticals

Nov 19, 2025 – Singapore – In a decisive move to combat the fundamental mechanisms of aging, Immortal Dragons, the visionary $40 million longevity fund, today announced its strategic backing of Etheros Pharmaceuticals. This pioneering biotechnology company is developing a revolutionary class of drugs aimed at neutralizing oxidative stress, a primary culprit in cellular aging and a host of age-related diseases. The investment highlights Immortal Dragons' unwavering commitment to supporting groundbreaking science that has the potential to not only treat disease but also extend healthy human lifespan.

At the heart of Etheros's innovation are proprietary water-soluble fullerene derivatives. These molecules act as powerful catalytic antioxidants, a significant leap forward from traditional antioxidant strategies. Oxidative damage, caused by reactive oxygen species (ROS) or free radicals, is a well-established contributor to the aging process and a wide array of chronic conditions. Etheros's compounds are engineered to overcome the limitations of potency and biodistribution that have hindered previous approaches, offering a promising new weapon in the fight against age-related decline.

A Breakthrough in Antioxidant Therapeutics

Etheros's technology is born from the Nobel Prize-winning field of fullerene chemistry. The company has masterfully engineered these carbon spheres into water-soluble therapeutics that mimic the body’s own powerful antioxidant enzymes, such as superoxide dismutase (SOD). Unlike conventional antioxidants that are consumed after a single reaction, Etheros’s catalytic compounds can neutralize thousands of ROS molecules per second, offering a dramatically more potent and sustained effect.

The scientific foundation for this platform is robust, with years of research demonstrating remarkable results in various disease models. Studies have shown significant neuroprotective effects in models of ALS and Parkinson's disease. Most notably, one study revealed a 14% median lifespan extension in middle-aged mice, an effect comparable to caloric restriction. Furthermore, elderly mice treated with the Etheros compound displayed substantially improved learning and memory. Building on this success, the company is advancing its lead compound, which has already established a wide safety margin and shown positive effects in a mouse model of Alzheimer's disease.

A Partnership Forged in Vision and Purpose

The investment in Etheros Pharmaceuticals is a perfect embodiment of Immortal Dragons' core mission: to target the fundamental pillars of aging. By addressing the pervasive issue of oxidative damage, Etheros is tackling a process that underpins numerous chronic illnesses, from neurodegeneration to cardiovascular disease.

“Immortal Dragons are both bold and thoughtful. That is a difficult mix to get right. And from a practical perspective, they have also been great to work with; really supportive.” said Dr. Jack Scannell, CEO of Etheros.

Boyang Wang, founder of Immortal Dragons, explained the strategic rationale: "Etheros represents an investment in a differentiated platform addressing oxidative stress through catalytic antioxidants. Their approach to this fundamental aspect of aging biology complements our portfolio strategy and contributes to our mission in the longevity space."

Charting the Path to Human Trials

With the new capital infusion from Immortal Dragons, Etheros Pharmaceuticals is poised to accelerate the development of its lead compound toward human clinical trials. The company’s strategy is to first seek proof-of-concept in indications with clear biomarkers and clinical endpoints, while simultaneously building a long-term platform to address major age-related diseases.

Key upcoming milestones include completing the necessary regulatory studies for an Investigational New Drug (IND) filing, scaling up GMP manufacturing of their lead candidate, and developing robust biomarkers to measure drug activity in both animal studies and future human trials. This multi-pronged approach provides several pathways to demonstrate the transformative potential of their technology.

About Immortal Dragons:

Immortal Dragons (https://www.id.life/) is a purpose-driven longevity fund headquartered in Singapore. The fund invests in cutting-edge, high-impact technologies and currently supports more than 15 portfolio companies. Beyond conventional investments, the fund advances longevity advocacy through book translation and publishing, translation of longevity leaders' talks, hosting a leading Chinese-language longevity podcast, and providing sponsorships and grants to longevity initiatives and conferences.

For Press Inquiries:
Boyang Wang
Founder, Immortal Dragons
press@id.life